| 2020-05 |
Establishing the common oncology data model for the national biobank consortium of Taiwan |
Journal of Clinical Oncology. 2020 May;38(15, Suppl.):Meeting Abstract e19283. |
|
| 2020-05 |
EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435) |
Journal of Clinical Oncology. 2020 May;38(15, Suppl.):Abstract number TPS4669. |
|
| 2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study |
Journal of Clinical Oncology. 2020 Feb;38(4):Meeting Abstract 477. |
|
| 2020-02 |
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data |
Journal of Clinical Oncology. 2020 Feb;38(4):Meeting Abstract 383. |
|
| 2019-10 |
Chemo-radiotherapy in adjuvant therapy of curatively resected pancreatic cancer: Lesions from TCOG T3207 study |
Annals of Oncology. 2019 Oct;30(Suppl. 6):75. |
 |
| 2019-10 |
Interpretation the results of adjuvant chemotherapy in curatively resected pancreatic cancer |
Annals of Oncology. 2019 Oct;30(Suppl. 6):vi 78. |
|
| 2019-10 |
Randomised phase 3 study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) - Integrate II |
Annals of Oncology. 2019 Oct;30(Suppl. 6):137. |
|
| 2019-10 |
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 |
Annals of Oncology. 2019 Oct;30(Suppl. 5):319. |
|
| 2019-02 |
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC) |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 319. |
|
| 2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2 |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 8. |
|
| 2019-02 |
A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number TPS468. |
|
| 2019-02 |
Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 269. |
|
| 2018-12 |
FOXO3a-driven alternation of metabolism dictates the gemcitabine sensitivity |
Cancer Science. 2018 Dec;109(Suppl. 2):871. |
|
| 2018-12 |
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation |
Cancer Science. 2018 Dec;109(Suppl. 2):866. |
|
| 2018-12 |
The epidemiology of gastric cancer in the era of H. pylori eradication: A nation-wide registry-based study in Taiwan |
Cancer Science. 2018 Dec;109(Suppl. 2):1437. |
|
| 2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study |
Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 200P. |
|
| 2018-11 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype |
Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 153O. |
|
| 2018-11 |
TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
Annals of Oncology. 2018 Nov;29(Suppl. 9):50. |
|
| 2018-10 |
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P. |
|
| 2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P. |
|
| 2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1 |
Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251. |
|
| 2018-10 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P. |
|
| 2018-10 |
Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P. |
|
| 2018-10 |
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD. |
|
| 2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286. |
|
